Skip to content
OpenCapital
Get started

Bio-Rad Laboratories, Inc. BIO.B Payments for (proceeds from) derivative instruments, operating activities

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept bio:Paymentsforproceedsfromderivativeinstrumentsoperatingactivities.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s payments for (proceeds from) derivative instruments, operating activities.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s payments for (proceeds from) derivative instruments, operating activities?
Bio-Rad Laboratories, Inc. (BIO.B) reported payments for (proceeds from) derivative instruments, operating activities of -$9.9M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s payments for (proceeds from) derivative instruments, operating activities changed year-over-year?
Bio-Rad Laboratories, Inc.'s payments for (proceeds from) derivative instruments, operating activities decreased by 219.3% year-over-year, from $8.3M to -$9.9M.